Devonian Health Group Inc
Research Devonian Health Group Inc (GSD) on Bullrun: market cap CAD 25.72M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGSD
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 25.72M
- Financial periodQ1 2026
- RevenueCAD 487.82K
- Net income-CAD 2.24M
- Free cash flow-CAD 5.34M
- Gross margin6.8%
Valuation Snapshot
latest market cap is CAD 25.72M.
About Devonian Health Group Inc
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis.
Frequently asked questions
What is Devonian Health Group Inc's market cap?
Devonian Health Group Inc's market capitalization is CAD 25.72M.
What does Devonian Health Group Inc do?
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population;